

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI696560

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	Novosanis NV	02/28/2023
RECEIVING PARTY DATA		
Company Name:	IDEVAX BV	
Street Address:	Bijkhoevelaan 32c	
City:	Wijnegem	
State/Country:	BELGIUM	
Postal Code:	2110	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Patent Number:	9931472	
CORRESPONDENCE DATA		
Fax Number:	8013281707	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	8015339800	
Email:	mstringham@wnlaw.com	
Correspondent Name:	Michelle Stringham	
Address Line 1:	60 E. South Temple, Suite 1000	
Address Line 4:	Salt Lake City, UTAH 84111	
ATTORNEY DOCKET NUMBER:	22213.1	
NAME OF SUBMITTER:	Michelle Stringham	
SIGNATURE:	Michelle Stringham	
DATE SIGNED:	12/16/2024	
Total Attachments: 5		
source=IDEVAX_WW_Patent_Assignment_20230228_signed#page1.tiff		
source=IDEVAX_WW_Patent_Assignment_20230228_signed#page2.tiff		
source=IDEVAX_WW_Patent_Assignment_20230228_signed#page3.tiff		
source=IDEVAX_WW_Patent_Assignment_20230228_signed#page4.tiff		
source=IDEVAX_WW_Patent_Assignment_20230228_signed#page5.tiff		

CONFIRMATORY PATENT ASSIGNMENT - WORLDWIDE

WHEREAS, Novosanis NV, Bijkhoevelaan 32c, 2110 Wijnegem, Belgium (hereinafter "**Vendor**") was the owner of the patent applications and patents and the inventions described in the attached Schedule A ("**Patents**");

WHEREAS, IDEVAX BV, Bijkhoevelaan 32c, 2110 Wijnegem, Belgium (hereinafter referred to as "**Purchaser**") wished to acquire the Patents;

WHEREAS, under the terms of an Asset Purchase Agreement (the "**APA**") made as of December 28, 2020 (the "**Effective Date**"), Vendor has sold, assigned, transferred and conveyed to Purchaser its entire right, title and interest in and to the Patents; and

WHEREAS the parties have agreed to execute and deliver this Patent Assignment for recordal and/or registration with governmental authorities including, but not limited to, the Canadian Intellectual Property Office and the United States Patent and Trademark Office.

NOW THEREFORE, in consideration for the execution of the APA, the payment of the consideration stipulated in the APA and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:

1. Vendor hereby sells, assigns, transfers and conveys to Purchaser, and confirms that it has sold, assigned, transferred and conveyed to Purchaser, effective as of the Effective Date, its entire, right, title and interest in and throughout the world in and to the Patents, including:
 - a. the inventions disclosed in the Patents;
 - b. any and all related Canadian, United States and foreign patent applications disclosing said inventions, including provisionals, non-provisionals, divisions, continuations, continuations-in-part, and continued prosecution applications and any other related Canadian, United States and foreign patent applications thereof, along with all rights of priority created by said patent applications under relevant international agreements; and
 - c. all patents which may be granted on any and all of said applications, including extensions, reissues and reexamination certificates thereof,

the foregoing to be held and enjoyed by the Purchaser to the full end of the term or terms for which said patents may be granted, as fully and entirely as the same would have been held by Vendor had this sale, assignment, transfer and conveyance not been made.


2. Vendor authorizes any governmental authorities to record and register this Patent Assignment upon request by Purchaser. Vendor shall take such steps and actions following the date hereof, including the execution of any documents, files, registrations or other similar items, to ensure that the Assigned Patents are properly assigned to Vendor, or any successor or assignee thereto.
3. The terms of the APA are incorporated herein by this reference. The parties hereto acknowledge and agree that terms and conditions contained in the APA shall not be superseded hereby but shall remain in full force and effect to the full extent provided therein. In the event of any conflict or inconsistency between the terms of the APA and the terms hereof, the terms of the APA shall

govern.


4. This Patent Assignment shall be governed by, construed and interpreted in accordance with the laws of Belgium.
5. This Patent Assignment is for the benefit of the parties and shall be binding upon their respective successors and assigns, as applicable.
6. This Patent Assignment may be executed in counterparts and via facsimile or email, each of which counterpart shall constitute an original and both of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, a duly authorized officer of Vendor and Purchaser have executed this assignment on the date listed below.


Novosanis NV

By: 
Name: Koen Beyers
Title: Sr. Director
Place: Wijnegem
Date: Feb 28th 2023


IDEVAX BV

By: 
Name: Vanessa Vankerckhoven
Title: CEO
Place: Antwerp
Date: Feb 28th 2023

Witness for Signature of Novosanis NV

By: 
Name: Mieke Trekels
Place: Wijnegem
Date: Feb 28th 2023

Witness for Signature of IDEVAX BV

By: 
Name: Alejandra Ríos Cortés
Place: Wijnegem
Date: Feb 28th 2023

SCHEDULE A

PATENTS/PATENT APPLICATIONS				
Portfolio 1 – Intradermal Injection Device ("GEN 0")				
Country	Application No.	Registration No.	Former Ref. No.	Current Ref. No.
Belgium	2013/0275	1021643	13103NA00BE	VAX-ID (BE) PBE30940
Belgium	13719048.4	2844317	Validation from 13093NA00EP	VAX-ID (BE-VAL) PBE30940-VAL
Brazil	112014025838-4	BR112014025838-4	13093NADMBR	VAX-ID (BR) PBR30940
Switzerland	13719048.4	2844317	Validation from 13093NA00EP	VAX-ID (CH) PCH30940
China	201380031848.4	ZL 201380031848.4	13093NASHCN	VAX-ID (CN) PCN30940
Czech Republic	13719048.4	2844317	Validation from 13093NA00EP	VAX-ID (CZ) PCZ30940
Germany	13719048.4	602013056173.7	Validation from 13093NA00EP	VAX-ID (DE) PDE30940
Europe	13719048.4	2844317	13093NA00EP	VAX-ID (EP) PEP30940
Spain	13719048.4	2844317	Validation from 13093NA00EP	VAX-ID (ES) PES30940
France	13719048.4	2844317	Validation from 13093NA00EP	VAX-ID (FR) PFR30940
United Kingdom	13719048.4	2844317	Validation from 13093NA00EP	VAX-ID (GB-VAL) PGB30940-VAL
Hong Kong	15109359.9	1208637	13093NASHHK	VAX-ID (HK) PHK30940
Hungary	13719048.4	2844317	Validation from 13093NA00EP	VAX-ID (HU) PHU30940
Ireland	13719048.4	2844317	Validation from 13093NA00EP	VAX-ID (IE) PIE30940
India	9645/DELNP/2014		13093NAPMIN	VAX-ID (IN) PIN30940
Italy	13719048.4	2844317	Validation from 13093NA00EP	VAX-ID (IT) PIT30940
Japan	2015-506227	6435451	13093NAA0JP	VAX-ID (JP) PJP30940
The Netherlands	2010649	2010649	13103NA00NL	VAX-ID (NL) PNL30940
The Netherlands	13719048.4	2844317	Validation from 13093NA00EP	VAX-ID (NL-VAL) PNL30940-VAL
Poland	13719048.4	2844317	Validation from 13093NA00EP	VAX-ID (PL) PPL30940
Portugal	13719048.4	2844317	Validation from 13093NA00EP	VAX-ID (PT) PPT30940

PATENTS/PATENT APPLICATIONS				
Portfolio 1 – Intradermal Injection Device ("GEN 0")				
Country	Application No.	Registration No.	Former Ref. No.	Current Ref. No.
Sweden	13719048.4	2844317	Validation from 13093NA00EP	VAX-ID (SE) PSE30940
Turkey	13719048.4	2844317	Validation from 13093NA00EP	VAX-ID (TR) PTR30940
United States	14/395,133	9,931,472	13093NAWNUS	VAX-ID (US) PUS30940
United Kingdom	1206766.6	N/A	11266NA00GB	VAX-ID (GB) PGB30940
PCT Application	PCT/EP2013/057990	N/A	13093NA00WO	VAX-ID (PCT) PPCT30940

PATENTS/PATENT APPLICATIONS				
Portfolio 2 – Injection Device ("GEN 1")				
Country	Application No.	Registration No.	Former Ref. No.	Current Ref. No.
Brazil	112018070046-0		17035NAPIBR	VAX-IDE 2000 (BR) PBR30969
Canada	3,019,486		17035NAPICA	VAX-IDE 2000 (CA) PCA30969
China	201780022990.0	ZL 201780022990.0	17035NAPICN	VAX-IDE 2000 (CN) PCN30969
Europe	17715155.2		17035NAR00EP	VAX-IDE 2000 (EP) PEP30969
Hong Kong	19125647.8		17035NASHHK	VAX-IDE 2000 (HK) PHK30969
India	201827040785		17035NAPIIN	VAX-IDE 2000 (IN) PIN30969
Japan	2018-551995	7197361	17035NAPIJP	VAX-IDE 2000 (JP) PJP30969
Korea	10-2018-7029936		17035NAPIKR	VAX-IDE 2000 (KR) PKR30969
Mexico	MX/a/2018/011894		17035NAPIMX	VAX-IDE 2000 (MX) PMX30969
United States	16/090,295	11,413,405	17035NAWNUS	VAX-IDE 2000 (US) PUS30969
Europe	16163466.2		15173NA00EP	
PCT Application	PCT/EP2017/057898	N/A	17035NA00WO	VAX-IDE 2000 (PCT) PPCT30969

PATENTS/PATENT APPLICATIONS				
Portfolio 3 – Intradermal Injection Device ("GEN 2")				
Country	Application No.	Registration No.	Former Ref. No.	Current Ref. No.
PCT Application	PCT/EP2020/079267	N/A	GEN-2	VAX-ID GEN-2 (PCT) PPCT30920
United States	62/916,157	N/A	GEN-2	VAX-ID GEN-2 (USPR) PPR30920

LEGAL_1:78759325.1